Reply  by Zamboni, Paolo et al.
LETTERS TO THE EDITORRegarding “A prospective open-label study of
endovascular treatment of chronic cerebrospinal
venous insufficiency”
I read with great interest the article written by Zamboni et al1
regarding the open-label study of endovascular treatment of
chronic cerebrospinal venous insufficiency (CCSVI) in patients
with multiple sclerosis (MS), which was published in December
2009. The study reports significant reductions in the annualized
relapse rate in 65 MS patients (10 with primary progressive, 35
with relapse remitting, and 20 with secondary progressive) who
underwent treatment of central venous stenosis with measurable
pressure gradients with a mean follow-up of 18 months. The
percent freedom from relapse increased from 27% to 50% (P 
.0014), and the annualized relapse rate fell from 0.9 0.8 to 0.7
1 (P .11). All of the patients were said to be receiving treatment
with a U.S. Food and Drug Administration-approved drug.
Zamboni et al2 also published an article on CCSVI in patients
with MS in the Journal of Neurology, Neurosurgery, and Psychiatry
in 2009. That article, which was received by the journal on July 2,
2008, reports on the central venous pathology in 65 patients with
MS (10 with primary progressive, 35 with relapse remitting, and
20with secondary progressive). In this report, 28 of the 65 patients
(43.1%) were not receiving medical treatment at the time of the
evaluation.
Unfortunately, neither article gives the treatment date range,
but the fact that both articles have the exact same number of MS
patients and the exact same number of patients with primary
progressive, relapse-remitting, and secondary progressive disease
suggests that both of the articles report the same patient pool.
Combining these factual concerns suggest that some, if not all, of
the response to angioplasty is due to initiating medical therapy—
not angioplasty.
This concern is supported by realizing that the annualized
relapse rate for MS patients diagnosed with CCSVI and treated
with angioplasty fell from 0.9  0.8 to 0.7  1.1 This should be
compared with the annual relapse rate for patients treated with
interferon -1a, which is 0.55.3 Based on these relapse rates,
patients receiving approved medical therapy have a lower relapse
rate than those treated with angioplasty.
It is estimated that 350,000 people in the United States have
the diagnosis ofMS,4 of those, 50% require help ambulating within
15 years. The disease is life altering; the suicide risk is high, even in
young patients with mild symptoms.5 If the above concerns are
correct, presenting this procedure as an effective treatment of MS
has created an unfortunate urban myth that desperate MS sufferers
will cling to. The conflict of interest is obvious; the lay press is
already reporting that patients with MS are seeking out physicians
around the world who offer this therapy—for $10,000 per treat-
ment.6
Jay Requarth, MD
Section of Vascular and Interventional Radiology
Department of Radiologic Sciences
Wake Forest University Baptist Medical Center
Winston Salem, NC
REFERENCES
1. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Gianesini S, Bar-
tolomei I, Mascoli F, Salvi F. A prospective open-label study of endovas-
cular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg
2009;50:1348-58.
17482. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall’Ara
S, et al. Chronic cerebrospinal venous insufficiency in patients with
multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80:392-9.
3. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et
al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl
J Med 2006;355:1124-40.
4. Anderson BG, Ellenberg JH, Leventhal CM, Reingold SC, Rodriguez
M, Silbert DH. Revised estimate of the prevalence of multiple sclerosis in
the United States. Ann Neurol 1992;31:333-6.
5. Weinshenker BG, Bass B, Rice GP,Noseworthy J, CarriereW, Baskerville
J, et al. The natural history of multiple sclerosis: a geographically based
study. Brain 1989;112:133-46.
6. Kingston A, Gulli C. The ‘miracle cure.’ MacLean’s 2010; April 26:459.
doi:10.1016/j.jvs.2010.05.136
Reply
We thank Dr Requarth for giving us the opportunity to add
further data and discussion to our article. However, he certainly
read with interest—but not carefully—our article, because on page
1350 line 12, we explain that the cohort of patients was the same as
previously reported.1 In the former article about these patients,2
we described chronic cerebrospinal venous insufficiency (CCSVI),
a syndrome demonstrated by the combination of Doppler ultra-
sound imaging and catheter angiography and characterized by
outflow problems of the major extracranial cerebral veins. We also
described the frequent association of CCSVI with multiple sclero-
sis (MS).2
Dr Requarth is right in reporting that the average relapse in
the relapsing remitting clinical course of MS, under disease-
modifying treatment (DMT), is 0.55/year. This particular clinical
course was present in 35 patients of the cohort, and 33 (94%) were
under DMT (Table). The other 26 patients without treatment, as
correctly observed byDr Requarth, were in differentMS categories
and are characterized by clinical courses without relapses, as re-
ported in the last paragraph of page 1349. For instance, the
primary progressive clinical course of MS is actually orphan of any
treatment (10 patients in our cohort), and quite frequently, pa-
tients with severe disability and secondary progressive MS refuse
any treatment because it is completely ineffective (16 patients in
our cohort; Table).3
Table. Treatment used at least once during the previous
3 years in the patient cohort with chronic cerebrospinal
venous insufficiency multiple sclerosis (MS)
Treatment Drug MS cases, No.
Immunosuppressants Mitoxantrone,
cyclophosphamide,
azathioprine
22
Immunomodulators Interferon-,
glatiramer acetate
31
Corticosteroids IV high-dose
methylprednisolone
95a
Treatment refusal 16 SP
2 RR
PP cases No available effective
treatment
10
IV, Intravenous; PP, primary progressive; RR, relapsing remitting; SP,
secondary progressive.
aNo. of cycles of treatment in acute exacerbations.
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remitting course (Table), they had experienced a higher than
expected relapse rate of 0.9/year. However, the patients in our
population had MS associated with CCSVI. For this peculiar
association, we measured in our pilot study if angioplasty treat-
ment of CCSVI could modify the neurologic outcome of MS.
The endovascular treatment, despite the 47% restenosis rate
recorded in the internal jugular veins, reduced, although not
significantly, the annualized relapse rate from 0.9 to 0.7. Relapse
did recur in 50% of patients compared with 77% registered in the
previous 2 years (P  .0014). As stated in the article, relapses as
well as new T1 gadolinium-positive lesions did not occur in pa-
tients with patency of the major cerebral veins: two objectively
measured facts and not a sham effect. Actually, we are conducting
long-term follow-up of the same cohort.
We think it would be highly irresponsible to not report to
colleagues such preliminary results. The excitement is understand-
able for patients and is linked to two reasons. The first is the
awareness that MS, ranging from 56% to 100% of cases, can be
associated with a major vascular problem.2,4-6 The second is that
the latter may have a resolution through a minimally invasive
surgery.
Knowing if this is a sham or a real therapeutic effect for MS is
a precise responsibility of the medical community, and not an
opinion expressed in a scientific letter. As stated on page 1357 line
35, a randomized, controlled, double-blind study is the only tool
that can answer the question of Dr Requarth. This will start in the
next months involving several centers in Italy.
Paolo Zamboni, MD
Roberto Galeotti, MD
Erica Menegatti, PhD
Anna Maria Malagoni, MD, PhD
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Regarding “A prospective open-label study of
endovascular treatment of chronic cerebrospinal
venous insufficiency”
In the article “A prospective open-label study of endovascular
treatment of chronic cerebrospinal venous insufficiency,” by Zam-
boni et al,1 the authors compared pre- and post-therapy outcomes
with two-sample statistical analyses as though the outcomes arose
from independent groups of patients (page 1351 of the article).
They did not present within-patient results or use paired statistical
tests for change in venous pressure or neurologic outcomes. Their
reported use of Fisher exact test to analyze annualized relapse rates
is not appropriate because those data are not proportions or
numbers of patients. Tables IV and V fail to state the number of
patients included in these results. Onemight suspect that not all 35
relapsing remitting patients contribute to Table IV, as no counts
yield percentages of 27% (9: 26%, 10: 29%) or 50% (17: 49%, 18:
51%), for example.
Given the attention that Dr Zamboni’s results have received,
the reader would welcome an addendum with clarification and
information that is more complete. It is possible that the appropri-
ate paired testing would provide similar or greater degrees of
statistical significance, bolstering hope for the effectiveness of
percutaneous transluminal angioplasty in treating multiple sclero-
sis patients.
Joan Skurnick, PhD
Department of Preventive Medicine and Community Health
New Jersey Medical School
Newark, NJ
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Reply
Our study is a pilot study with promising results. It shows two
main shortcomings: the lack of a control group and blinded clinical
assessors. We chose to use statistical tests to underestimate rather
than exalt our findings, precisely because of the above limitations.
The tests suggested by you, as you noted at the end of your letter,
provide even greater degrees of statistical significance. Our policy is
to be as prudent as we can, waiting for randomized control trial
angioplasty results. The main message of our study is the safety and
the feasibility of venous angioplasty in patients affected by chronic
cerebrospinal venous insufficiency associated with multiple sclero-
sis (CCSVI-MS).1
However, differences in quality of life and multiple sclerosis
functional composite among neurologic outcomes were re-assessed
also with paired t test, as you requested in your letter, and were
significantly different. For instance, MSFC in relapsing remitting
patients by comparing baselinewith 18months value showed a highly
significant improvement of the motor and cognitive function ex-
pressed by such functional composite test (P .0001).
Differences in preoperative and postoperative pressure were
assessed with the two-tailed Mann-Whitney test, as reported at
page 1351 of our article.1
